Manzo Pharmaceuticals, Inc. engages in the provision of pharmaceutical preparations services. The company is headquartered in North York, Ontario. The company went IPO on 2001-07-11. The firm also develops its lactose intolerance product, for which it holds an exclusive patent license. The firm's primary products are dietary supplements, probiotics and natural remedies. The firm's subsidiary, Manzo Pharmaceuticals LLC (Manzo), is an alternative healthcare company with patents for a probiotic remedy for lactose intolerance. The firm also owns other products, including a remedy for babies suffering from colic and/or digestive gas. Manzo's Lacto-Freedom probiotic is a probiotic that aids in the digestion of lactose-containing foods, designed specifically for people with lactose sensitivity.
根据最新的财务报表(Form-10K),VAALCO Energy Inc 的总资产为 $0,净亏损为 $0
MNZO 的关键财务比率是什么?
VAALCO Energy Inc 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
Exxsun Corp 的收入按细分市场或地理位置如何划分?
VAALCO Energy Inc 最大收入来源是 Crude Oil, Natural Gas and Natural Gas Liquids,在最近的收益报告中收入为 359,272,000。就地区而言, Gabon 是 VAALCO Energy Inc 的主要市场,收入为 181,738,000。